Syngene International Limited Stock Price Today (NSE: SYNGENE)
Syngene International Limited
Fundamental Score
Syngene International Limited Share Price — Live NSE/BSE Price, Fundamentals & Analysis
Syngene International Limited share price today is ₹380.10, up +0.33% on NSE/BSE as of 16 September 2026. Syngene International Limited (SYNGENE) is a Mid-cap company in the Healthcare Research, Analytics & Technology sector with a market capitalisation of ₹15.34K (Cr). The 52-week high for SYNGENE share price is ₹678.95 and the 52-week low is ₹374.20. At a P/E ratio of 69.11x, SYNGENE is currently trading above its industry average P/E of 39.78x. 0
Syngene International Limited Share Price Chart — NSE/BSE Historical Performance
Syngene International Limited share price chart: -3.74% return over the past month. 52-week high ₹678.95, 52-week low ₹374.20.
Syngene International Limited — Last 10 Trading Days
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| ₹376.10 | ₹382.40 | ₹374.20 | ₹380.10 | 2.68L (Cr) | |
| ₹382.95 | ₹383.80 | ₹377.25 | ₹378.85 | 3.38L (Cr) | |
| ₹383.25 | ₹383.60 | ₹375.55 | ₹382.65 | 3.73L (Cr) | |
| ₹390.00 | ₹390.00 | ₹383.00 | ₹384.00 | 1.88L (Cr) | |
| ₹386.80 | ₹388.60 | ₹382.60 | ₹386.80 | 3.59L (Cr) | |
| ₹389.30 | ₹390.65 | ₹383.50 | ₹387.55 | 4.82L (Cr) | |
| ₹395.00 | ₹396.30 | ₹387.25 | ₹389.30 | 4.44L (Cr) | |
| ₹399.70 | ₹403.15 | ₹394.30 | ₹395.60 | 5.22L (Cr) | |
| ₹398.80 | ₹403.00 | ₹397.00 | ₹400.80 | 3.75L (Cr) | |
| ₹400.00 | ₹403.95 | ₹397.10 | ₹398.60 | 5.94L (Cr) |
Syngene International Limited — Last 12 Months Price History
| Month | Open | High | Low | Close | Change |
|---|---|---|---|---|---|
| ₹402.00 | ₹403.95 | ₹374.20 | ₹380.10 | -5.45% | |
| ₹386.50 | ₹419.50 | ₹384.00 | ₹400.75 | +3.69% | |
| ₹443.00 | ₹449.95 | ₹383.25 | ₹385.90 | -12.89% | |
| ₹443.00 | ₹462.49 | ₹430.93 | ₹439.50 | -0.79% | |
| ₹467.35 | ₹492.25 | ₹436.05 | ₹442.00 | -5.42% | |
| ₹395.05 | ₹518.55 | ₹380.00 | ₹467.65 | +18.38% | |
| ₹413.15 | ₹428.00 | ₹387.05 | ₹389.90 | -5.63% | |
| ₹467.10 | ₹512.95 | ₹418.10 | ₹422.20 | -9.61% | |
| ₹650.05 | ₹678.95 | ₹467.70 | ₹473.45 | -27.17% | |
| ₹651.50 | ₹665.30 | ₹623.65 | ₹651.00 | -0.08% | |
| ₹654.55 | ₹673.40 | ₹608.60 | ₹648.30 | -0.95% | |
| ₹623.30 | ₹667.85 | ₹617.55 | ₹650.10 | +4.30% |
Returns & Performance
Return on Equity (ROE)
Profit generated per ₹1 of shareholder equity
Return on Capital (ROCE)
Returns generated on total capital deployed
Oper. Profit Margin (5Y Avg)
Average operating profit margin over 5 years
Dividend Yield
Annual dividend as % of current share price
Syngene International Limited Valuation Check
Price to Earnings (P/E)
Share price ÷ earnings per share. Lower = cheaper
Industry Avg P/E
Average P/E of all peers in this sector
Market Capitalisation
Total market value of all outstanding shares
Growth Engine
Profit Growth (Quarterly YoY)
Net profit growth vs same quarter last year
Revenue Growth (Quarterly YoY)
Revenue growth vs same quarter last year
Revenue Growth (5-Year CAGR)
Compounded annual revenue growth over 5 years
EPS Growth (5-Year CAGR)
Earnings per share growth over 5 years
Net Profit Growth (5-Year CAGR)
Compounded annual net profit growth over 5 years
Balance Sheet Health
Debt to Equity Ratio
Total debt ÷ equity. Below 0.5 = financially healthy
Interest Coverage Ratio
EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably
Free Cash Flow (5-Year Total)
Cash left after capex over 5 years. Positive = self-funded growth
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Syngene International Limited Fundamental Analysis & Valuation Benchmarking
Educational evaluation of SYNGENE across key market metrics for learning purposes.
Positive Indicators
8 factors identified
Strong Operating Margins (30.05%)
Observation: Healthy 5-year operating margins indicate pricing power and cost control.
Analysis: OPM >15% suggests operational efficiency and competitive advantages.
Conservative Debt Levels (D/E: 0.00)
Observation: Low leverage provides financial flexibility and reduced risk.
Analysis: Conservative debt structure offers resilience during economic downturns.
Strong Interest Coverage (9.42x)
Observation: Earnings comfortably cover interest obligations.
Analysis: Interest coverage >5x indicates low financial distress risk.
Healthy Liquidity Position (Current Ratio: 1.64)
Observation: Strong short-term liquidity to meet obligations.
Analysis: Current ratio >1.5 indicates good working capital management.
Strong Cash Generation (₹1910.30 Cr over 5Y)
Observation: Healthy free cash flow generation supports growth and returns.
Analysis: Strong FCF provides flexibility for dividends, debt reduction, and growth investments.
Balanced Promoter Holding (52.68%)
Observation: Optimal balance between promoter control and public float.
Analysis: Promoter holding in 50-75% range provides management alignment.
Strong Institutional Confidence (FII+DII: 40.35%)
Observation: Significant professional investor participation.
Analysis: High institutional holding often signals thorough due diligence.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral.
Analysis: Absence of share pledging eliminates potential forced-selling pressure.
Risk Factors
7 factors identified
Below-Average Return on Equity (0.00%)
Observation: Returns on equity are below industry benchmarks.
Analysis: ROE <10% may indicate inefficient capital utilization. Consider monitoring for operational improvements and management effectiveness.
Suboptimal ROCE (8.43%)
Observation: Returns on capital employed are below expectations.
Analysis: ROCE <10% suggests potential inefficiencies in capital allocation.
Premium Valuation Risk (P/E: 69.11x)
Observation: High valuation multiples may limit upside potential.
Analysis: Elevated P/E ratios require strong growth execution to justify current valuations.
Profit Decline Concern (-11.82%)
Observation: Significant year-over-year profit contraction observed.
Analysis: Declining profitability requires investigation into underlying causes.
Revenue Contraction (-15.84%)
Observation: Sales decline may indicate market challenges or competitive pressures.
Analysis: Negative revenue growth requires analysis of market conditions.
Weak Earnings Growth (-5.02% CAGR)
Observation: Below-average 5-year EPS growth performance.
Analysis: Low EPS growth may not keep pace with inflation.
Stagnant Profit Growth (-0.98% CAGR)
Observation: Limited 5-year profit growth trajectory.
Analysis: Low profit growth may indicate scalability challenges or market maturity.
Syngene International Limited vs Healthcare Research, Analytics & Technology Peers
Peer Comparison - Healthcare Research, Analytics & Technology
Compare Syngene International Limited with 8 other companies in the same sector
| Company Info | Fundamental | Valuation | Profitability | Financial Health | Growth | Dividend | ||||
|---|---|---|---|---|---|---|---|---|---|---|
Company Company name | Score Bull Run comprehensive fundamental score based on 20+ metrics | Price Current trading price of the stock | Market Cap Total value of all shares in the market | P/E Price per share divided by earnings per share | ROE Net income divided by shareholder equity | ROCE Earnings before interest and tax divided by capital employed | Debt/Eq Total debt divided by total equity | Profit 5Y Average annual profit growth over 5 years | Sales 5Y Average annual sales growth over 5 years | Dividend Annual dividend per share divided by price per share |
Syngene International LimitedSyngene Interna...Selected✓ SYNGENE • 539268 | 35.4/100 | ₹380.10₹380 | ₹15344.64₹15344.64 | 69.11Average 69.1 Average | 0.00%Poor 0.00% Poor | 8.43%Poor 8.43% Poor | 0.00Excellent 0.0 Excellent | -0.98%Poor -0.98% Poor | 11.35%Good 11.35% Good | 0.30% |
Indegene LimitedIndegene Limite... INDGN • 544172 | 57/100 | ₹582.80₹583 | ₹14016.34₹14016.34 | 34.88Average 34.9 Average | 13.94%Average 13.94% Average | 17.29%Good 17.29% Good | 0.00Excellent 0.0 Excellent | 23.02%Excellent 23.02% Excellent | 29.44%Excellent 29.44% Excellent | 0.39% |
Suven Life Sciences LimitedSuven Life Scie... SUVEN • 530239 | 11.4/100 | ₹358.55₹359 | ₹9465.47₹9465.47 | — — | -78.80%Poor -78.80% Poor | -78.35%Poor -78.35% Poor | 0.00Excellent 0.0 Excellent | — — | -12.00%Poor -12.00% Poor | 0.00% |
Vimta Labs LimitedVimta Labs Limi... VIMTALABS • 524394 | 63.6/100 | ₹623.00₹623 | ₹2782.94₹2782.94 | 34.88Average 34.9 Average | 18.55%Good 18.55% Good | 23.39%Excellent 23.39% Excellent | 0.01Excellent 0.0 Excellent | 29.35%Excellent 29.35% Excellent | 14.09%Good 14.09% Good | 0.35% |
TAKE LimitedTAKE Limited... TAKE • 532890 | 31.2/100 | ₹15.99₹16 | ₹236.55₹236.55 | 18.59Average 18.6 Average | 42.11%Excellent 42.11% Excellent | 18.49%Good 18.49% Good | 0.00Excellent 0.0 Excellent | 15.08%Excellent 15.08% Excellent | -41.25%Poor -41.25% Poor | 0.00% |
NOVELIX PHARMACEUTICALS LIMITENOVELIX PHARMAC... NOVELIX • 536565 | 56.9/100 | ₹79.00₹79 | ₹166.57₹166.57 | 45.85Average 45.8 Average | 8.00%Poor 8.00% Poor | 9.96%Poor 9.96% Poor | 0.09Excellent 0.1 Excellent | 22.72%Excellent 22.72% Excellent | 151.69%Excellent 151.69% Excellent | 0.00% |
Bilcare LimitedBilcare Limited... BI • 526853 | 28.9/100 | ₹93.01₹93 | ₹147.94₹147.94 | 26.80Average 26.8 Average | 1.66%Poor 1.66% Poor | 5.56%Poor 5.56% Poor | 3.15Poor 3.1 Poor | 16.32%Excellent 16.32% Excellent | 3.33%Average 3.33% Average | 0.00% |
Adeshwar Meditex LtdAdeshwar Medite... ADESHWAR • 543309 | 24.6/100 | ₹16.30₹16 | ₹23.52₹23.52 | 19.47Average 19.5 Average | 3.38%Poor 3.38% Poor | 6.02%Poor 6.02% Poor | 0.16Excellent 0.2 Excellent | -6.68%Poor -6.68% Poor | -3.19%Poor -3.19% Poor | 0.00% |
Vanta Bioscience LtdVanta Bioscienc... VANTABIO • 540729 | 23.9/100 | ₹19.60₹20 | ₹13.94₹13.94 | 163.55Average 163.6 Average | 0.76%Poor 0.76% Poor | 1.39%Poor 1.39% Poor | 1.80Average 1.8 Average | -24.21%Poor -24.21% Poor | -28.62%Poor -28.62% Poor | 0.00% |
Top Healthcare Research, Analytics & Technology Stocks
View all →By Bull Run Score
By Return on Equity
By Market Cap
- Indegene Limited share price14016.34 Cr
- Suven Life Sciences Limited share price9465.47 Cr
- Vimta Labs Limited share price2782.94 Cr
- TAKE Limited share price236.55 Cr
- NOVELIX PHARMACEUTICALS LIMITE share price166.57 Cr
Syngene International Limited PE Ratio History
Historical price-to-earnings ratio for SYNGENE — last 5 years
| Year | EPS (₹) | Price (₹) | P/E Ratio |
|---|---|---|---|
| FY 2025 | ₹12.34 | ₹651.00 | 52.8x |
| FY 2024 | ₹12.69 | ₹858.45 | 67.6x |
| FY 2023 | ₹11.51 | ₹701.45 | 60.9x |
| FY 2022 | ₹9.82 | ₹585.55 | 59.6x |
P/E = year-end price ÷ diluted EPS from annual filings. Source: NSE/BSE via Bull Run.
Syngene International Limited Dividend History
Annual cash dividends paid by SYNGENE — dividend yield 0.30%
| Financial Year | Dividends Paid (₹ Cr) |
|---|---|
| FY 2025 | ₹50.30 Cr |
| FY 2024 | ₹50.30 Cr |
| FY 2023 | ₹40.10 Cr |
Cash dividends from annual cash flow statements. Past dividends do not guarantee future payments. Not investment advice.
Syngene International Limited Quarterly Performance
Latest quarterly metrics for SYNGENE — revenue growth and profit growth vs same quarter last year
Revenue Growth (YoY)
-15.84%
Latest quarter vs same quarter previous year
Net Profit Growth (YoY)
-11.82%
Latest quarter net profit vs same quarter previous year
5-Year Revenue CAGR
11.35%
Compounded annual revenue growth over 5 years
5-Year Profit CAGR
-0.98%
Compounded annual net profit growth over 5 years
Syngene International Limited Technical Indicators
SMA 50, SMA 200, RSI and volume signals for SYNGENE — calculated from daily price history
Momentum is balanced — neither overbought nor oversold.
Technical indicators are for educational purposes only. Not investment advice.
Syngene International Limited Financial Statements
Annual income statement, balance sheet and cash flow for Syngene International Limited (SYNGENE) — sourced from NSE/BSE filings.
Financial Results & Statements
Latest quarterly, annual and period-wise financial data for Syngene International Limited
About SYNGENE (Syngene International Limited)
Syngene International Limited (SYNGENE) is listed on the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE) of India. The company operates in the Healthcare Research, An...alytics & Technology sector with a current market capitalisation of ₹15.34K (Cr). Syngene International Limited has delivered a Return on Equity (ROE) of 0.00% and a ROCE of 8.43%. The debt-to-equity ratio stands at 0.00, reflecting the company's capital structure. Investors tracking SYNGENE share price can monitor key metrics including P/E ratio, promoter holding of 52.68%, and quarterly earnings growth.
Company Details
Key Leadership
SYNGENE Share Price: Frequently Asked Questions
What is the current share price of Syngene International Limited?
Syngene International Limited (SYNGENE) trades at ₹380.10 on NSE and BSE. Market cap ₹15.34K (Cr). Educational data only.
What is the P/E ratio of Syngene International Limited?
Syngene International Limited has a P/E of 69.11x vs industry average 39.78x.
What is the Bull Run score for Syngene International Limited?
Syngene International Limited has a Bull Run score of 35.4/100 based on 25+ financial parameters.
Does Syngene International Limited pay dividends?
Syngene International Limited has a dividend yield of 0.30%. Past dividends don't guarantee future payments.
What is the ROE of Syngene International Limited?
Syngene International Limited has ROE of 0.00%. Higher ROE indicates better use of shareholder equity.
What is the debt-to-equity ratio of Syngene International Limited?
Syngene International Limited has debt-to-equity of 0.00.
Is Syngene International Limited a good investment?
Bull Run gives Syngene International Limited a score of 35.4/100. This is not investment advice — consult a SEBI-registered advisor.